[go: up one dir, main page]

HK1173655B - 用於治療對抗有絲分裂劑具抗性癌症的n-(4-((3-(2-氨基-4-嘧啶基)-2-吡啶基)氧基)苯基)-4-(4-甲基-2-噻吩基)-1-酞嗪胺 - Google Patents

用於治療對抗有絲分裂劑具抗性癌症的n-(4-((3-(2-氨基-4-嘧啶基)-2-吡啶基)氧基)苯基)-4-(4-甲基-2-噻吩基)-1-酞嗪胺 Download PDF

Info

Publication number
HK1173655B
HK1173655B HK13100715.9A HK13100715A HK1173655B HK 1173655 B HK1173655 B HK 1173655B HK 13100715 A HK13100715 A HK 13100715A HK 1173655 B HK1173655 B HK 1173655B
Authority
HK
Hong Kong
Prior art keywords
cancer
amg
tumor
cells
agent
Prior art date
Application number
HK13100715.9A
Other languages
German (de)
English (en)
French (fr)
Other versions
HK1173655A1 (zh
Inventor
Marc Payton
Richard Kendall
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc. filed Critical Amgen Inc.
Priority claimed from PCT/US2010/048247 external-priority patent/WO2011031842A1/en
Publication of HK1173655A1 publication Critical patent/HK1173655A1/zh
Publication of HK1173655B publication Critical patent/HK1173655B/zh

Links

HK13100715.9A 2009-09-11 2010-09-09 用於治療對抗有絲分裂劑具抗性癌症的n-(4-((3-(2-氨基-4-嘧啶基)-2-吡啶基)氧基)苯基)-4-(4-甲基-2-噻吩基)-1-酞嗪胺 HK1173655B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24152709P 2009-09-11 2009-09-11
US61/241,527 2009-09-11
PCT/US2010/048247 WO2011031842A1 (en) 2009-09-11 2010-09-09 N-4 ( - ( ( 3- ( 2 -amino-4 pyrimidinyl) -2 -pyridinyl) oxy) phenyl) -4- (4-methyl-2-thienyl) -1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
HK15106028.6A Division HK1205457A1 (zh) 2009-09-11 2013-01-16 N-4(-((3-(2-氨基-4-嘧啶基)-2-吡啶基)氧基)苯基)-4- (4-甲基-2-噻吩基)-1-酞嗪胺用於治療對抗有絲分裂劑具抗藥性的癌症

Related Child Applications (1)

Application Number Title Priority Date Filing Date
HK15106028.6A Addition HK1205457A1 (zh) 2009-09-11 2013-01-16 N-4(-((3-(2-氨基-4-嘧啶基)-2-吡啶基)氧基)苯基)-4- (4-甲基-2-噻吩基)-1-酞嗪胺用於治療對抗有絲分裂劑具抗藥性的癌症

Publications (2)

Publication Number Publication Date
HK1173655A1 HK1173655A1 (zh) 2013-05-24
HK1173655B true HK1173655B (zh) 2015-08-07

Family

ID=

Similar Documents

Publication Publication Date Title
EP2475368B1 (en) N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridin yl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer
JP6347795B2 (ja) 癌治療のための新規の組成物および方法
JP6754071B2 (ja) メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用
KR20170017932A (ko) Ｍｄｍ２ 억제제의 간헐적 투여
KR20070064414A (ko) 세포 증식 제어를 위한 ｃｈｋ1 억제제의 용도
JP2016535014A (ja) がんの処置のための医薬の組合せ
TW201609094A (zh) 治療癌症之新穎方法
KR20220008870A (ko) 노치-활성화 유방암을 치료하기 위한 비스플루오로알킬-1,4-벤조디아제피논 화합물
HK1173655B (zh) 用於治療對抗有絲分裂劑具抗性癌症的n-(4-((3-(2-氨基-4-嘧啶基)-2-吡啶基)氧基)苯基)-4-(4-甲基-2-噻吩基)-1-酞嗪胺
US20190133998A1 (en) Treatment of tumors with inhibitors of cxcl12 signaling and subtherapeutic amounts of chemotherapeutic agents
EP3070092B1 (en) 3-phenyl-thiazolo[3,2-a]benzimidazole derivatives as aldehyde dehydrogenase 1 (aldh-1) modulators for the treatment of breast cancer or leukemia, and for manipulating cultured aldh-1 positive breast cancer or leukemia cells
CN112999236B (zh) 乌本苷用于治疗脑干胶质瘤的用途
WO2010085462A1 (en) Method for treating triple negative breast cancer